First patient enrolled in Phase IIa clinical trial of ophthalmology drug for delaying myopia in children in China
October 27, 2025
Source: drugdu
124
On October 26, Yuanda Pharmaceutical announced that the first patient has been enrolled in a Phase IIa clinical study in China of its innovative ophthalmic drug, GPN00884, for slowing the progression of myopia in children. This marks the beginning of a crucial phase of dosing and preliminary efficacy assessment for GPN00884. This Phase IIa trial is a randomized, double-blind, placebo-controlled study enrolling over 80 myopic subjects aged 6 to 12 years. The study aims to preliminarily evaluate the efficacy and safety of GPN00884 eye drops in slowing the progression of myopia in children.
Source：https://finance.eastmoney.com/a/202510263544490960.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
